Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Pfizer
Pfizer
Eli Lilly and Company
Canadian Cancer Trials Group
Masonic Cancer Center, University of Minnesota
Northwestern University
Altor BioScience
National Cancer Institute (NCI)
National Institutes of Health Clinical Center (CC)